Inflammatory mediators in inflammatory bowel disease

Current Opinion in Gastroenterology

Volumn 14, Issue 4, 1998, Pages 295-299

  Dotan, Iris ^a   Rachmilewitz, Daniel ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOTRIENE B4 RECEPTOR ANTAGONIST; NEUROPEPTIDE; NITRIC OXIDE SYNTHASE; OXYGEN RADICAL; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE A2 RECEPTOR BLOCKING AGENT;

ARACHIDONIC ACID METABOLISM; COLITIS; ENTERITIS; EOSINOPHIL; MAST CELL; MEDIATOR; SHORT SURVEY; ULCERATIVE COLITIS;

EID: 0031857501     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199807000-00004     Document Type: Short Survey

References (19)

1. Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, •• Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor *alpha* for Crohn's disease, N Engl J Med 1997, 337:1029-1035. The largest study until now demonstrating significant effect of a single infusion of an anti-tumor necrosis factor monoclonal antibody in patients with moderate-to-severe treatment-resistant Crohn's disease.
2. Peterson JW, Dickey DW, Saini SS, Gourley W, Klimpel GR, Chopra AK: Phospholipase A2 activating protein and idiopathic inflammatory bowel disease. Gut 1996, 39:698-704.
3. Hawkey CJ, Dube LM, Rountree LV, Linnen PJ, Lancaster JF, and the European Zileuton Study Group for Ulcerative Colitis: A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. Gastroenterology 1997, 112:718-724.
4. Roberts WG, Simon TJ, Berlin RG, Haggit RC, Snyder ES, Stenson WF, Hanauer SB, Reagan JE, Cagliola A, Tanaka WK, et al.: Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterology 1997, 112:725-732.
5. Schmidt C, Baumeister B, Kipnowski J, Schiermeyer-Dunkhase B, Vetter H: Alteration of prostaglandin E2 and leukotriene B4 synthesis in chronic inflammatory bowel disease. Hepatogastroenterology 1996, 43:1508-1512.
6. Taniguchi T, Tsukada H, Nakamura H, Kodama M, Fukuda K, Tominaga M, • Seino Y: Effects of a thromboxane A2 receptor antagonist in an animal model of inflammatory bowel disease. Digestion 1997, 58:476-478. Simple, well-conducted methodologically, and suggests that thromboxane blockade may have a role in the treatment of IBD.
7. Collins CE, Benson MJ, Burnham WR, Ramptom DS: Picotamide inhibition of excess in vitro thromboxane B2 release by colorectal mucosa in inflammatory bowel disease. Aliment Pharmacol Ther 1996, 10:315-320.
8. Campbell JM, Fahey GC, Lichtensteiger CA, Demichele SJ. Garleb KA: An enteral formula containing fish oil, indigestible oligosaccharides, gum arabic and antioxidants affects plasma and colonic phospholipid fatty acid and prostaglandin profiles in pigs. J Nutr 1997, 127:137-145.
9. Kald B, Smedh K, Olaison G, Sjodahl R, Tagesson C: Platelet-activating factor acetylhydrolase activity in intestinal mucosa and plasma of patients with Crohn's disease, Digestion 1996, 57:472-477.
10. Watanabe T, Kubota Y, Muto T: Substance P containing nerve fibers in • rectal mucosa of ulcerative colitis. Dis Colon Rectum 1997, 40:718-725. An interesting new method for staining and quantitation of substance P-containing nerve fibers in the intestinal mucosa.
11. Yamamoto H, Morise K, Kusugami K, Furusawa A, Konagaya T, Nishio Y, Kaneko H, Uchida K, Nagai H, Mrrsuma T, Nagura H: Abnormal neuropeptide concentration in rectal mucosa of patients with inflammatory bowel disease. J Gastroenterol 1996, 31:525-532.
12. Kimura H, Miura S, Shigematsu T, Ohkubo N, Tsuzuki Y, Kurose I, Higuchi •• H, Akiba Y, Hokari R, Hirokawa M, et al.: Increased nitric oxide production and inducible nitric oxide synthase activity in colonic mucosa of patients with active ulcerative colitis and Crohn's disease, Dig Dis Sci 1997, 42:1047-1054. A "multilevel" work correlating tissue activities of NOS isoforms. plasma levels of NO metabolites, and clinical and histologic meaning, demonstrating a significant increase of these substances in the inflamed tissues.
13. Tanaka S, Miura S, Kimura H, Ohkubo N, Tsuzuki Y, Fukumura D, Serizawa H, Kurose I, Mori M, Ishii H: Amelioration of chronic inflammation by ingestion of elemental diet in a rat model of granulomatous enteritis. Dig Dis Sci 1997, 42:408-419.
14. Ribbons KA, Currie MG, Connor JR, Manning PT, Allen PC, Didier P, •• Ratterree MS, Clark DA, Miller MJS: The effect of inhibitors of inducible nitric oxide synthase on chronic colitis in the rhesus monkey. J Pharmacol Exp Ther 1997, 280:1008-1015. In the first work of its kind in a primate, this interesting model resembling UC showed failure of iNOS inhibition to improve colitis.
15. McCafferty DM, Mudget JS, Swain MG. Kubes P: Inducible nitric oxide synthase plays a critical role in resolving intestinal inflammation. Gastroenterology 1997, 112:1022-1027.
16. Hoffenberg EJ, Deutsch J, Smith S, Sokol RJ: Circulating antioxidant • concentrations in children with inflammatory bowel disease. Am J Clin Nutr 1997, 65:1482-1488. Interesting results suggesting that the oxidative burden in children with IBD may cause decrease of circulating antioxidants.
17. Ramakrishna BS, Varghese R, Jayakumar S, Mathan M, Balasubramanian KA: Circulating antioxidants in ulcerative colitis and their relationship to disease severity and activity. J Gastroenterol Hepatol 1997, 12:490-494.
18. Yoshikawa T, Yamaguchi T, Yoshida N, Yamamoto H, Kitazumi S, • Takahashi S, Naito Y, Kondo M: Effect of Z-103 on TNB-induced colitis in rats. Digestion 1997, 58:464-468. An established model of colitis in which a presumed antioxidant has therapeutic effect similar to that of sulfasalazine.
19. Bischoff SC, Grabowsky J. Manns MP: Quantification of inflammatory mediators in stool samples of patients with inflammatory bowel disorders and controls, Dig Dis Sci 1997, 24:394-403.